NV-001 in the Treatment of Advanced Solid Tumors

Phase 1 Recruiting 20 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors.

Timeline

Start: 2023-12-01
Primary completion: 2025-03-01
Completion: 2025-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NV-001	Vaccine	—	—

NV-001 in the Treatment of Advanced Solid Tumors

Summary

Timeline

Drugs

Indications